BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27166361)

  • 1. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis.
    Kastritis E; Papassotiriou I; Terpos E; Roussou M; Gavriatopoulou M; Komitopoulou A; Skevaki C; Eleutherakis-Papaiakovou E; Pamboucas C; Psimenou E; Manios E; Giannouli S; Politou M; Gakiopoulou H; Papadopoulou E; Stamatelopoulos K; Tasidou A; Dimopoulos MA
    Blood; 2016 Jul; 128(3):405-9. PubMed ID: 27166361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
    Karakaya B; Tombak A; Serin MS; Tiftik N
    Hematology; 2016 Jun; 21(5):295-9. PubMed ID: 26872106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
    Pépin M; Kleinjan A; Hajage D; Büller HR; Di Nisio M; Kamphuisen PW; Salomon L; Veyradier A; Stepanian A; Mahé I
    J Thromb Haemost; 2016 Feb; 14(2):306-15. PubMed ID: 26589836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
    Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
    J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
    Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
    J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.
    Sonneveld MA; Franco OH; Ikram MA; Hofman A; Kavousi M; de Maat MP; Leebeek FW
    Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2446-2451. PubMed ID: 27737864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.
    Guo R; Yang J; Liu X; Wu J; Chen Y
    J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28374895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application Value of Plasma vWF and ADAMTS-13 in Evaluating Postoprative Vascular Endothelial Injury and Prognosis in Children with VSD].
    Wang XY; Zhang QW; Shen YM; Liu JF; Li WZ; Jia KG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):189-196. PubMed ID: 36765498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
    Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Papasotiriou I; Fotiou D; Migkou M; Roussou M; Kanellias N; Ziogas D; Dialoupi I; Eleutherakis Papaiakovou E; Kastritis E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):23-28. PubMed ID: 30224328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
    Sins JWR; Schimmel M; Luken BM; Nur E; Zeerleder SS; van Tuijn CFJ; Brandjes DPM; Kopatz WF; Urbanus RT; Meijers JCM; Biemond BJ; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1392-1402. PubMed ID: 28457019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
    Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
    BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Plasma Levels of ADAMTS-13, von Willebrand Factor, VWFpp, and Fibrin-Related Markers in Patients With Systemic Sclerosis Having Thrombosis.
    Habe K; Wada H; Higashiyama A; Akeda T; Tsuda K; Mori R; Kakeda M; Matsumoto T; Ohishi K; Yamanaka K; Katayama N; Mizutani H
    Clin Appl Thromb Hemost; 2018 Sep; 24(6):920-927. PubMed ID: 29130325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmatic ADAMTS-13 metalloprotease and von Willebrand factor in children with cyanotic congenital heart disease.
    Soares RP; Bydlowski SP; Nascimento NM; Thomaz AM; Bastos EN; Lopes AA
    Braz J Med Biol Res; 2013 Apr; 46(4):375-81. PubMed ID: 23558858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty.
    Liu L; Ling J; Ma Z; Yuan Q; Pan J; Yang H
    Mol Med Rep; 2015 Apr; 11(4):3015-20. PubMed ID: 25482054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated preoperative von Willebrand factor is associated with perioperative thrombosis in infants and neonates with congenital heart disease.
    Hunt R; Hoffman CM; Emani S; Trenor CC; Emani SM; Faraoni D; Kimchi-Sarfaty C; Ibla JC
    J Thromb Haemost; 2017 Dec; 15(12):2306-2316. PubMed ID: 28981194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiological Shear Stress: Therapeutic Implications for Left Ventricular Assist Device-Associated Bleeding.
    Bartoli CR; Kang J; Restle DJ; Zhang DM; Shabahang C; Acker MA; Atluri P
    JACC Heart Fail; 2015 Nov; 3(11):860-9. PubMed ID: 26454844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure.
    De Filippis V; Lancellotti S; Maset F; Spolaore B; Pozzi N; Gambaro G; Oggianu L; Calò LA; De Cristofaro R
    Biochem J; 2012 Mar; 442(2):423-32. PubMed ID: 22091998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAMTS-13-VWF axis in sickle cell disease patients.
    Ladeira VS; Barbosa AR; Oliveira MM; Ferreira LGR; de Oliveira Júnior WV; de Oliveira Renó C; Reis EA; Chaves DG; Dusse LMS; Dos Santos HL; de Barros Pinheiro M; Rios DRA
    Ann Hematol; 2021 Feb; 100(2):375-382. PubMed ID: 33404693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.